Key result
In a systematic review of 141 pregnant women treated with thrombolytics for serious thrombotic events, maternal death occurred in 2.8% and major bleeding in 8.5%.
Why the study?
Is the use of thrombolytic agents safe in pregnant women with serious thrombotic events?
Population
141 pregnant women with serious thrombotic events pooled from 65 articles.
Design
Systematic_review
Authors
Loading...
Thrombolytics in pregnancy warrant caution given observed risks; leaves open need for randomized data to guide use.
Systematic Review (n=141)
Is the use of thrombolytic agents safe in pregnant women with serious thrombotic events?
Thrombolytic therapy in pregnancy for life-threatening thrombotic events appears to have an acceptable safety profile, with complication rates seemingly not higher than in nonpregnant patients.
Gomes et al. (2018) conducted a systematic review in Serious thrombotic events (DVT, PE, stroke, PVT) in pregnancy (n=141). Thrombolytic agents was evaluated on Maternal and fetal outcomes (maternal deaths, bleeding, fetal death, miscarriages, preterm delivery). In a systematic review of 141 pregnant women treated with thrombolytics for serious thrombotic events, maternal death occurred in 2.8% and major bleeding in 8.5%.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: